Physicochemical Properties
| Molecular Formula | C21H29CLN4O6 |
| Molecular Weight | 468.931164503098 |
| Exact Mass | 468.177 |
| CAS # | 2703746-41-0 |
| Related CAS # | D-Ala-Lys-AMCA;375822-19-8;D-Ala-Lys-AMCA TFA |
| PubChem CID | 139600271 |
| Appearance | Light yellow to yellow solid powder |
| Hydrogen Bond Donor Count | 6 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 10 |
| Heavy Atom Count | 32 |
| Complexity | 737 |
| Defined Atom Stereocenter Count | 2 |
| SMILES | CC1=C(C(=O)OC2=C1C=CC(=C2)N)CC(=O)NCCCC[C@@H](C(=O)O)NC(=O)[C@@H](C)N.Cl |
| InChi Key | CUYFZQGMNMFDIC-KKJWGQAZSA-N |
| InChi Code | InChI=1S/C21H28N4O6.ClH/c1-11-14-7-6-13(23)9-17(14)31-21(30)15(11)10-18(26)24-8-4-3-5-16(20(28)29)25-19(27)12(2)22;/h6-7,9,12,16H,3-5,8,10,22-23H2,1-2H3,(H,24,26)(H,25,27)(H,28,29);1H/t12-,16+;/m1./s1 |
| Chemical Name | (2S)-6-[[2-(7-amino-4-methyl-2-oxochromen-3-yl)acetyl]amino]-2-[[(2R)-2-aminopropanoyl]amino]hexanoic acid;hydrochloride |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | D-Ala-Lys-AMCA hydrochloride (25, 50, and 150 μM, 3 hours) is translocated to Caco-2 cells and liver cancer cells [1]. In all small intestine segments, absorptive enterocytes take up D-Ala-Lys-AMCA (25 μM, 10 min) hydrochloride, but fluorescence is completely missing in colon samples [2]. |
| References |
[1]. Specific expression of proton-coupled oligopeptide transporter 1 in primary hepatocarcinoma-anovel strategy for tumor-targeted therapy. Oncol Lett. 2017 Oct;14(4):4158-4166. [2]. Intestinal peptide transport: ex vivo uptake studies and localization of peptide carrier PEPT1. Am J Physiol Gastrointest Liver Physiol. 2001 Sep;281(3):G697-704. |
Solubility Data
| Solubility (In Vitro) |
H2O: 100 mg/mL (213.25 mM) DMSO: 100 mg/mL (213.25 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.33 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.44 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1325 mL | 10.6626 mL | 21.3251 mL | |
| 5 mM | 0.4265 mL | 2.1325 mL | 4.2650 mL | |
| 10 mM | 0.2133 mL | 1.0663 mL | 2.1325 mL |